Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal Natural Killer (NK)/T-cell lymphoma, nasal type: The NK-cell tumor study group study

Journal of Clinical Oncology

Volumn 29, Issue 33, 2011, Pages 4410-4416

  Yamaguchi, Motoko ^a   Kwong, Yok Lam ^k   Kim, Won Seog ^l   Maeda, Yoshinobu ^b   Hashimoto, Chizuko ^c   Suh, Cheolwon ^m   Izutsu, Koji ^d   Ishida, Fumihiro ^f   Isobe, Yasushi ^e   Sueoka, Eisaburo ^g   Suzumiya, Junji ^h   Kodama, Takao ⁱ   Kimura, Hiroshi ^j   Hyo, Rie ^j   Nakamura, Shigeo ^j   Oshimi, Kazuo ^e,n   Suzuki, Ritsuro ^j  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

^d Kanto Teishin Hospital   (Japan)

^e JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g SAGA UNIVERSITY   (Japan)

^h Fukuoka University Chikushi Hospital   (Japan)

ⁱ UNIVERSITY OF MIYAZAKI   (Japan)

^j NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k UNIVERSITY OF HONG KONG   (Hong Kong)

^l Sungkyunkwan University School of Medicine   (South Korea)

^m University of Ulsan College of Medicine   (South Korea)

ⁿ EISAI RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; COTRIMOXAZOLE; DEXAMETHASONE; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; METHOTREXATE; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERAMYLASEMIA; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOFIBRINOGENEMIA; HYPONATREMIA; INFECTION; INTESTINE PERFORATION; LEUKOPENIA; LIVER FUNCTION; LYMPHOCYTE COUNT; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NAUSEA; NEUTROPENIA; NK T CELL LYMPHOMA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PANCREATITIS; PARTIAL THROMBOPLASTIN TIME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; STEROID THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; FEMALE; HUMANS; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; NOSE NEOPLASMS; RECURRENCE;

EID: 81755172136     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.6287     Document Type: Article

References (30)

1. Chan JKC, Jaffe ES, Ralfkiaer E: Extranodal NK/T-cell lymphoma, nasal type, in Jaffe ES, Harris NL, Stein H (eds): World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001, pp 204-207
2. Chan JKC, Quintanilla-Martinez L, Ferry JA: Extranodal NK/T-cell lymphoma, nasal type, in Swerdlow SH, Campo E, Harris NL (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, International Agency for Research on Cancer, 2008, pp 285-288
3. Lee J, Suh C, Park YH, et al.: Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study. J Clin Oncol 24:612-618, 2006 (Pubitemid 46630424)
4. Kim TM, Lee SY, Jeon YK, et al.: Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: A national survey of the Korean Cancer Study Group. Ann Oncol 19:1477-1484, 2008
5. Au WY, Weisenburger DD, Intragumtornchai T, et al.: Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: A study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 113:3931-3937, 2009
6. Suzuki R, Suzumiya J, Yamaguchi M, et al.: Prognostic factors for mature natural killer (NK) cell neoplasms: Aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 21:1032-1040, 2010
7. Yamaguchi M, Tobinai K, Oguchi M, et al.: Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 27:5594-5600, 2009
8. Kim SJ, Kim K, Kim BS, et al.: Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol 27:6027-6032, 2009
9. Kwong YL, Anderson BO, Advani R, et al.: Management of T-cell and natural-killer-cell neoplasms in Asia: Consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10: 1093-1101, 2009
10. Yamaguchi M, Kita K, Miwa H, et al.: Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 76:2351-2356, 1995
11. Egashira M, Kawamata N, Sugimoto K, et al.: P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 93:599-606, 1999 (Pubitemid 29035741)
12. Drénou B, Lamy T, Amiot L, et al.: CD3-CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Blood 89:2966-2974, 1997 (Pubitemid 27172584)
13. Murashige N, Kami M, Kishi Y, et al.: Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 130:561-567, 2005 (Pubitemid 43899760)
14. Suzuki R, Suzumiya J, Nakamura S, et al.: Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant 37:425-431, 2006 (Pubitemid 43250478)
15. Kwong YL: High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies. Bone Marrow Transplant 44:709-714, 2009
16. Yamaguchi M, Suzuki R, Kwong YL, et al.: Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 99:1016-1020, 2008 (Pubitemid 351997606)
17. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, 1979
18. Cheson BD, Horning SJ, Coiffier B, et al.: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244-1253, 1999 (Pubitemid 29162950)
19. Oshimi K, Kawa K, Nakamura S, et al.: NK-cell neoplasms in Japan. Hematology 10:237-245, 2005 (Pubitemid 41801140)
20. Kim GE, Cho JH, Yang WI, et al.: Angiocentric lymphoma of the head and neck: Patterns of systemic failure after radiation treatment. J Clin Oncol 18:54-63, 2000 (Pubitemid 30036336)
21. Suzuki R: Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia. Int J Hematol 92:697-701, 2010
22. Jaccard A, Gachard N, Marin B, et al.: Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase II study. Blood 117:1834-1839, 2011
23. Yong W, Zheng W, Zhu J, et al.: L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol 88:647-652, 2009
24. Tsukune Y, Isobe Y, Yasuda H, et al.: Activity and safety of combination chemotherapy with methotrexate, ifosfamide, l-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: A pilot study. Eur J Haematol 84:310-315, 2010
25. Ando M, Sugimoto K, Kitoh T, et al.: Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol 130:860-868, 2005 (Pubitemid 43899727)
26. Rodriguez J, Romaguera JE, Manning J, et al.: Nasal-type T/NK lymphomas: A clinicopathologic study of 13 cases. Leuk Lymphoma 39:139-144, 2000 (Pubitemid 30657816)
27. Nagafuji K, Fujisaki T, Arima F, et al.: L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 74:447-450, 2001 (Pubitemid 33760107)
28. Obama K, Tara M, Niina K: L-asparaginase-based induction therapy for advanced extranodal NK/T-cell lymphoma. Int J Hematol 78:248-250, 2003 (Pubitemid 37288512)
29. Matsumoto Y, Nomura K, Kanda-Akano Y, et al.: Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma 44:879-882, 2003 (Pubitemid 36410998)
30. Yong W, Zheng W, Zhang Y, et al.: L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 78:163-167, 2003 (Pubitemid 37021959)